Recent Finacing
Recent Raise
Nectin Therapeutics develops monoclonal antibodies and antibody-drug conjugates targeting the nectin/PVR (CD155) pathway; lead candidate NTX1088 blocks TIGIT/CD96 and restores DNAM1, now in Phase 1 for solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Nectin Therapeutics.
